CURE’s lung cancer page is an extensive resource of cancer information featuring the latest lung cancer news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on lung cancer.
September 14th 2022
Lumakras outperformed chemotherapy in reducing the risk of progression or death and improving quality of life for patients with KRAS G12C-mutated non-small cell lung cancer, study results showed.
September 13th 2022
An expert discusses what patients need to know about the recent FDA approval of Enhertu for HER2-mutant non-small cell lung cancer, an aggressive subtype of the disease.
September 12th 2022
When going through treatment for advanced-stage lung cancer, people would often talk to me like I was a child, or ignore me altogether and speak to my husband.
August 31st 2022
The first patient has been treated with H002, a novel drug being investigated for non-small cell lung cancer that is resistant to a prior EGFR TKI treatment.
August 25th 2022
More patients with pretreated non-small cell lung cancer saw their disease disappear with abivertinib compared to Tagrisso.
August 23rd 2022
When doctors told me that there was no more they could do for my stage 4 lung cancer, I refused to believe them, and wish other patients did the same.
August 11th 2022
The FDA’s approval of Enhertu marks the first approval of a drug for patients with HER2-mutant unresectable or metastatic non-small cell lung cancer.
August 11th 2022
The FDA approved Tabrecta for patients with non-small cell lung cancer who have a mutation that led to MET exon 14 skipping.
August 10th 2022
Imfinzi plus tremelimumab led to better overall survival outcomes compared to standard chemotherapy in patients with metastatic non-small cell lung cancer.
August 9th 2022
According to real-world data, EGFR C797X mutation is deemed the leading resistance mechanism to treatment with Tagrisso in patients with non-small cell lung cancer.
August 9th 2022
Sugemalimab demonstrated safe and efficacious results when given after concurrent chemoradiation therapy or short-course chemoradiation therapy for patients with lung cancer.
August 5th 2022
Treatment with Onivyde failed to best the chemotherapy topotecan in improving overall survival in patients with small cell lung cancer whose disease failed to respond to platinum-based first-line treatment, according to findings from a primary analysis of the phase 3 RESILIENT trial.
August 2nd 2022
Subcutaneous (injectable) Tecentriq had similar movement throughout the body, while saving on treatment time compared to intravenous administration of the drug in a group of patients with non-small cell lung cancer.
August 1st 2022
In honor of World Lung Cancer Day, CURE® compiled the five most-read lung cancer-related news items from 2022 that patients may have missed.
July 29th 2022
Watch Dr. Ravi Salgia, Dr. Erminia Massarelli, Dr. Jyoti Malhotra and Daniel Saez answer questions about advancements in lung cancer during the CURE Educated Patient Lung Cancer Summit.
July 28th 2022
Watch Dr. Jyoti Malhotra, from City of Hope, discuss advancements in advanced-stage non-small cell lung cancer during the CURE Educated Patient Lung Cancer Summit.
July 27th 2022
Watch Dr. Erminia Massarelli, from City of Hope, discuss advancements in early-stage non-small cell lung cancer during the CURE Educated Patient Lung Cancer Summit.
July 26th 2022
Watch Dr. Ravi Salgia, from City of Hope, discuss advancements in small cell lung cancer during the CURE Educated Patient Lung Cancer Summit.
July 25th 2022
Watch Nikki Martin, Dr. Ying-Chun Lo and Dr. Hossein Borghaei discuss overcoming barriers to receiving biomarker testing during the CURE Educated Patient Lung Cancer Summit.
July 24th 2022
Watch Elisabeth King, Dr. Edward S. Kim and Terri Conneran answer questions about targeted therapy during the CURE Educated Patient Lung Cancer Summit.
July 23rd 2022
Watch Dr. Edward S. Kim, from City of Hope, discuss targeted therapy during the CURE Educated Patient Lung Cancer Summit.
July 22nd 2022
Watch Elisabeth King, from City of Hope, discuss biomarker testing during the CURE Educated Patient Lung Cancer Summit.
July 21st 2022
Watch Dr. Farhad Mazdisnian, Dr. Terence Williams and Dr. Antoinette J. Wozniak answer questions about the basics of the disease during the CURE Educated Patient Lung Cancer Summit.
July 20th 2022
Watch Dr. Terrance M. Williams, from City of Hope, discuss radiation advances during the CURE Educated Patient Lung Cancer Summit.
July 19th 2022
Watch Dr. Farhard Mazdisnian, from City of Hope, discuss diagnosing early, locally advanced and metastatic disease, during the CURE Educated Patient Lung Cancer Summit.
July 18th 2022
Cosela tended to decrease myelosuppressive events — when the bone marrow is not working sufficiently to produce blood cells and platelets — in patients receiving chemotherapy for extensive-stage small cell lung cancer.
July 11th 2022
The first patient was dosed in a phase 2 trial studying the efficacy of sapanisertib in patients with NRF2-mutant relapsed/refractory lung cancer.
June 26th 2022
The stories in this issue of CURE illustrate how patients with cancer have become partners in therapeutic advances.
June 17th 2022
A phase 2a trial is kicking off to study frontline GB1211 with the immunotherapy agent Tecentriq in patients with advanced or metastatic non-small cell lung cancer.
June 16th 2022
Instead of waiting until the disease has progressed, researchers have begun analyzing the effects of using immunotherapy before or after surgery in patients with early-stage lung cancer. The results, according to experts, may be transformative for patients.